| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,200 | ₹3 0% | 2500% |
| - | - | 4,500 | ₹40 0% | 1250% |
| - | - | 4,700 | ₹5 0% | 1,1250% |
| - | - | 4,800 | ₹2 0% | 5,625-2.17% |
| - | - | 4,850 | ₹12.5 0% | 00% |
| - | - | 4,900 | ₹4.5 0% | 9,2500% |
| 1,8750% | ₹567 0% | 5,000 | ₹3.2 -8.57% | 8,375-18.29% |
| - | - | 5,050 | ₹8.55 0% | 00% |
| 6250% | ₹244.45 0% | 5,100 | ₹4.05 -34.67% | 6,125-47.87% |
| 6250% | ₹203.7 0% | 5,150 | ₹6.4 -10.48% | 3,500-12.5% |
| 3,625-6.45% | ₹314.4 -5.96% | 5,200 | ₹5.2 -21.21% | 24,1250% |
| 1,5000% | ₹283 0% | 5,250 | ₹7.3 -13.6% | 12,37550% |
| 9,5000% | ₹260.3 0% | 5,300 | ₹10.2 -15% | 16,500-11.40% |
| 3,875-20.51% | ₹174.35 -2.05% | 5,350 | ₹16 -10.36% | 25,8759.52% |
| 23,250-1.06% | ₹146 -19.64% | 5,400 | ₹24 2.56% | 36,7500.68% |
| 11,25011.11% | ₹90.15 -36.46% | 5,450 | ₹37 2.06% | 10,1251.25% |
| 73,2500.17% | ₹61.55 -42.36% | 5,500 | ₹59 13.57% | 32,750-26.61% |
| 24,875-31.61% | ₹39.3 -50.5% | 5,550 | ₹82.1 10.42% | 7,75014.81% |
| 48,87513.33% | ₹26 -53.73% | 5,600 | ₹121.3 21.11% | 16,125-5.14% |
| 6,0000% | ₹15.6 -59% | 5,650 | - | - |
| 59,7502.13% | ₹9 -65.31% | 5,700 | ₹209.55 0% | 1250% |
| 23,375-11.79% | ₹6.4 -63.42% | 5,750 | ₹237.45 0% | 1250% |
| 19,875-33.19% | ₹4.7 -62.24% | 5,800 | ₹300.5 0% | 5000% |
| 5,750-8% | ₹3.15 -50% | 5,900 | ₹388.55 0% | 2500% |
| 19,500-8.23% | ₹3.05 -32.22% | 6,000 | - | - |
| 2,2500% | ₹1.25 0% | 6,100 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
